A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes

Sponsor
Eli Lilly and Company
Study ID
NCT07765511
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Macupatide — DRUG
    Administered SC
  • Eloralintide — DRUG
    Administered SC
  • Placebo — DRUG
    Administered SC

Study Details

The main purpose of this study is to assess how well macupatide, when dosed alone and in combination with eloralintide, is tolerated and what side effects may occur in participants with obesity or overweight without Type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last about 4 months and will include 2 stays in the Clinical Research Unit (CRU), each lasting 3-5 nights.

Key Dates

First listed
Aug 14, 2026
Start date
Oct 31, 2026
Status verified
Aug 2026
Primary completion
Jun 30, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Macupatide ＋ placebo
    Macupatide and placebo administered subcutaneously (SC)
  • Experimental: Eloralintide + placebo
    Eloralintide and placebo administered SC
  • Experimental: Macupatide Dose A + Eloralintide
    Macupatide and Eloralintide administered SC
  • Experimental: Macupatide Dose B + Eloralintide
    Macupatide and Eloralintide administered SC
  • Placebo Comparator: Placebo
    Placebo administered SC

Primary Outcome Measure

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: End of Study (Week 25) ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Find similar trials

Nationwide
Obesity / overweight trialsEndocrinology trialsMetabolic health trialsWeight loss trials

Related Studies